- Datum25.04.2024
- Uhrzeit08:00 - 09:00 Uhr
- Veranstalter
XTB
Kein Moderator verfügbar
stock3 TerminalDu willst selbst ins Charting einsteigen?
Nutze das Charting-Widget auf dem stock3 Terminal für Deine eigene Analyse. Mehr Features. Mehr Werkzeuge. Mehr stock3.
Chart im Terminal öffnen
Passende Produkte
| WKN | Long/Short | KO | Hebel | Laufzeit | Bid | Ask |
|---|
Keine Ergebnisse gefunden
Wertentwicklung (L&S)
-0,26 %
Intraday
-1,31 %
1 Woche
-4,31 %
1 Monat
-8,19 %
Seit Jahresbeginn
-29,35 %
1 Jahr
-12,76 %
3 Jahre
78,22 %
5 Jahre
Wikifolio
Passender Service zu GENMAB AS
Webinar zu GENMAB AS
Kursinformationen (L&S)
- Tagestief / Hoch (€)-
- 52W-Tief / Hoch (€)244,800-394,400
- Jahrestief / Hoch (€)244,800-297,800
- Schlusskurs (Vortag)
- Eröffnungskurs
Wichtigste Eigenschaften
Dividenden von GENMAB AS
Keine Dividenden verfügbar
Termine von GENMAB AS
- Mai2GENMAB ASQ1 2024 Earnings Release
- Aug1GENMAB ASQ2 2024 Earnings Release
- Nov6GENMAB ASQ3 2024 Earnings Release
Beschreibung
Genmab is a Copenhagen-based biotechnology company specializing in antibody therapeutics for the treatment of cancer. Genmab's proprietary antibody technologies are DuoBody, HexaBody, DuoHexaBody, and HexElect. Johnson & Johnson partnered with Genmab to create Darzalex, which is regarded as the standard of care for multiple myeloma and is Genmab's leading product. Genmab also has Tepezza for thyroid eye disease (partnered with Horizon), Kesimpta for relapsing multiple sclerosis (partnered with Novartis), Rybrevant (partnered with Johnson & Johnson) for non-small cell lung cancer (NSCLC), Tivdak (partnered with Seagen) for cervical cancer, and Epkinly (partnered with AbbVie) for diffuse large B-cell lymphoma. Genmab has several pipeline candidates targeting other oncologic indications.
